These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 26310996)

  • 1. Alphavirus-based vaccines in melanoma: rationale and potential improvements in immunotherapeutic combinations.
    Zappasodi R; Merghoub T
    Immunotherapy; 2015; 7(9):981-97. PubMed ID: 26310996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alphavirus replicon particles expressing TRP-2 provide potent therapeutic effect on melanoma through activation of humoral and cellular immunity.
    Avogadri F; Merghoub T; Maughan MF; Hirschhorn-Cymerman D; Morris J; Ritter E; Olmsted R; Houghton AN; Wolchok JD
    PLoS One; 2010 Sep; 5(9):. PubMed ID: 20844763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways.
    Leitner WW; Hwang LN; deVeer MJ; Zhou A; Silverman RH; Williams BR; Dubensky TW; Ying H; Restifo NP
    Nat Med; 2003 Jan; 9(1):33-9. PubMed ID: 12496961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autologous, allogeneic tumor cells or genetically engineered cells as cancer vaccine against melanoma.
    Schadendorf D; Paschen A; Sun Y
    Immunol Lett; 2000 Sep; 74(1):67-74. PubMed ID: 10996630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Melanoma-associated tumor antigens and their clinical relevance to immunotherapy.
    Gattoni-Celli S; Cole DJ
    Semin Oncol; 1996 Dec; 23(6):754-8. PubMed ID: 8970598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of Alphaviral Vectors for Immunomodulation in Cancer Therapy.
    Zajakina A; Spunde K; Lundstrom K
    Curr Pharm Des; 2017; 23(32):4906-4932. PubMed ID: 28641531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolving role of tumor antigens for future melanoma therapies.
    Andrews MC; Woods K; Cebon J; Behren A
    Future Oncol; 2014 Jun; 10(8):1457-68. PubMed ID: 25052755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current immunotherapeutic strategies in malignant melanoma.
    Agostino NM; Ali A; Nair SG; Mosca PJ
    Surg Oncol Clin N Am; 2007 Oct; 16(4):945-73, xi. PubMed ID: 18022553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel recombinant alphaviral and adenoviral vectors for cancer immunotherapy.
    Osada T; Morse MA; Hobeika A; Lyerly HK
    Semin Oncol; 2012 Jun; 39(3):305-10. PubMed ID: 22595053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An alphavirus-based therapeutic cancer vaccine: from design to clinical trial.
    Singh A; Koutsoumpli G; van de Wall S; Daemen T
    Cancer Immunol Immunother; 2019 May; 68(5):849-859. PubMed ID: 30465060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Next generation of immunotherapy for melanoma.
    Kirkwood JM; Tarhini AA; Panelli MC; Moschos SJ; Zarour HM; Butterfield LH; Gogas HJ
    J Clin Oncol; 2008 Jul; 26(20):3445-55. PubMed ID: 18612161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alphavirus-based vaccines.
    Lundstrom K
    Curr Opin Mol Ther; 2002 Feb; 4(1):28-34. PubMed ID: 11883692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intratumoral immunotherapy for melanoma.
    Singh M; Overwijk WW
    Cancer Immunol Immunother; 2015 Jul; 64(7):911-21. PubMed ID: 26050024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanoma.
    Rozera C; Cappellini GA; D'Agostino G; Santodonato L; Castiello L; Urbani F; Macchia I; Aricò E; Casorelli I; Sestili P; Montefiore E; Monque D; Carlei D; Napolitano M; Rizza P; Moschella F; Buccione C; Belli R; Proietti E; Pavan A; Marchetti P; Belardelli F; Capone I
    J Transl Med; 2015 May; 13():139. PubMed ID: 25933939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of two cancer vaccines targeting tyrosinase: plasmid DNA and recombinant alphavirus replicon particles.
    Goldberg SM; Bartido SM; Gardner JP; Guevara-Patiño JA; Montgomery SC; Perales MA; Maughan MF; Dempsey J; Donovan GP; Olson WC; Houghton AN; Wolchok JD
    Clin Cancer Res; 2005 Nov; 11(22):8114-21. PubMed ID: 16299244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current status of melanoma vaccines.
    Kuhn CA; Hanke CW
    Dermatol Surg; 1997 Aug; 23(8):649-54; discussion 654-5. PubMed ID: 9256911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alphavirus vectors for cancer therapy.
    Quetglas JI; Ruiz-Guillen M; Aranda A; Casales E; Bezunartea J; Smerdou C
    Virus Res; 2010 Nov; 153(2):179-96. PubMed ID: 20692305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy of Melanoma.
    Snyder A; Zamarin D; Wolchok JD
    Prog Tumor Res; 2015; 42():22-9. PubMed ID: 26376963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review: dendritic cell immunotherapy for melanoma.
    Hadzantonis M; O'Neill H
    Cancer Biother Radiopharm; 1999 Feb; 14(1):11-22. PubMed ID: 10850282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunity to melanoma antigens: from self-tolerance to immunotherapy.
    Slingluff CL; Chianese-Bullock KA; Bullock TN; Grosh WW; Mullins DW; Nichols L; Olson W; Petroni G; Smolkin M; Engelhard VH
    Adv Immunol; 2006; 90():243-95. PubMed ID: 16730266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.